Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-07
2005-06-07
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253050, C514S253060, C514S253070, C514S307000, C514S314000, C546S146000, C546S148000, C546S150000, C546S165000, C546S166000, C546S139000, C546S153000, C546S168000, C546S169000, C544S363000
Reexamination Certificate
active
06903103
ABSTRACT:
Compound of formula (I):wherein:V represents a single bond or an alkylene chain,M represents a single bond or an alkylene chain,A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen,W represents a group of formula (i), (ii) or (iii):wherein:X represents carbonyl, sulphonyl or sulphoxide,G1, G2and G3are as defined in the description,T represents a fused phenyl group or a fused pyridyl group,R1represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched,R2aand R2b, which are the same or different, are as defined in the description,R3represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted,Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted,its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid.Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
REFERENCES:
AHA Medical/scientific Statement (Herbert C. Stary et al.) (http:/216.185.102.50/Scientific&statements/1995/179500005.html).
Candipan RC, et al. Arterioscler. Thromb. Vasc. Biol. 1996, 16, 44-50.
Cooke JP, et al. J. Clin. Invest. 1992, 90, 1168-1172.
Dillon GA, et al. Contemporary cardiology, vol. 4: Nitric oxide and the Cardiovascular System. Edited by Loscalzo J. and Vita J.A., 2000, 13, 207-225.
Eberhardt RT, et al. Contemporary cardiology, vol. 4: Nitric oxide and the Cardiovascular System. Edited by Loscalzo J. and Vita J.A., 2000, 13, 273-295.
Kauser K, et al. Am. J. Physiol. 2000, 278, H1679-H1685.
Ludmer PL, et al. N. Engl J. Med. 1986, 315, 1046-1051.
Napoli C, et al. Nitric Oxide 2001, vol. 5, No 2, 88-97.
Naruse K, et al. arterioscler. Thromb. 1994, 14, 746-752.
Schachinger V, et al. coronary Artery Disease 2001, vol. 12, No6, 435-443.
Wang BY, et al. J. Am. Coll. Cardiol. 1994, 23, 452-458.
Zeiher AM, et al. Circulation, 1991, 83, 391-401.
Bourguignon Marie-Pierre
Peglion Jean-Louis
Poitevin Christophe
Thollon Catherine
Vilaine Jean-Paul
Habte Kahsay
Les Laboratories Servier
Shah Mukund J.
The Firm of Hueschen and Sage
LandOfFree
Linear cyclic ureas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Linear cyclic ureas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Linear cyclic ureas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504423